8-K: Inozyme Pharma Announces Positive Interim Data for INZ-701 in End-Stage Kidney Disease Trial

Inozyme Pharma's INZ-701 showed positive interim results in a Phase 1 trial, significantly increasing plasma pyrophosphate levels in patients with end-stage kidney disease undergoing hemodialysis.

Summary

• Inozyme Pharma announced positive interim data from its Phase 1 SEAPORT 1 trial of INZ-701 in patients with end-stage kidney disease (ESKD) undergoing hemodialysis.
• The trial investigated the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of INZ-701 in adults with ESKD and low plasma pyrophosphate (PPi) levels.
• The study enrolled 11 patients who received weekly subcutaneous doses of 1.8 mg/kg of INZ-701 over a four-week period.
• Interim data from eight patients showed that INZ-701 significantly increased PPi levels, reaching normal ranges by week 3.
• The treatment also led to reductions in biomarkers of mineral metabolism, such as serum phosphate and fibroblast growth factor-23.
• INZ-701 was generally well-tolerated, with no drug-related treatment-emergent adverse events reported, except for one case of hyperkalemia.
• Consistent drug exposure was observed, and PK profiles were consistent with prior studies.
• Low titers of anti-drug antibodies (ADAs) were detected in three patients, but these were not associated with adverse events.
• The company plans to initiate a registrational trial of INZ-701 in patients with calciphylaxis in 2025, subject to regulatory alignment and sufficient funding.
• Enrollment for the ENERGY 3 pivotal trial of INZ-701 in pediatric patients with ENPP1 Deficiency is expected to be completed by the end of 2024, with topline data anticipated in early 2026.

Sentiment

Score: 8

Explanation: The document presents very positive interim clinical trial results, a clear path forward with a registrational trial, and a favorable safety profile. The need for additional funding is a minor concern, but the overall tone is optimistic.

Positives

• INZ-701 demonstrated a significant increase in PPi levels in ESKD patients, reaching normal ranges by week 3 of the trial.
• The drug showed a reduction in key biomarkers associated with vascular calcification, suggesting a potential benefit in mitigating this risk.
• The safety profile of INZ-701 was favorable, with no drug-related adverse events reported, except for one case of hyperkalemia.
• Consistent drug exposure and PK profiles were observed, indicating reliable dosing in dialysis patients.
• The company is planning a registrational trial for calciphylaxis in 2025, indicating progress towards a potential treatment for this condition.

Negatives

• Low titers of anti-drug antibodies (ADAs) were detected in three patients, although they were not associated with adverse events.
• One patient experienced hyperkalemia requiring urgent dialysis, although this was not considered drug-related.

Risks

• The company's ability to conduct ongoing clinical trials of INZ-701 for ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis is subject to risks.
• Enrolling patients in ongoing and planned trials may present challenges.
• Obtaining and maintaining necessary approvals from the FDA and other regulatory authorities is not guaranteed.
• The company needs to replicate positive results from early-stage trials in later clinical trials.
• Advancing the development of product candidates under anticipated timelines is subject to risks.
• The company needs to obtain, maintain, and protect intellectual property rights related to its product candidates.
• Managing expenses and complying with loan agreement covenants are ongoing risks.
• Raising the substantial additional capital needed to achieve business objectives is a significant risk.

Future Outlook

The company plans to initiate a registrational trial of INZ-701 in patients with calciphylaxis in 2025, subject to regulatory alignment and sufficient funding. They also expect to complete enrollment of the ENERGY 3 pivotal trial for ENPP1 Deficiency by the end of 2024, with topline data anticipated in early 2026.

Management Comments

• Douglas A. Treco, Ph.D., CEO and Chairman of Inozyme Pharma, stated that the interim data from the SEAPORT 1 trial demonstrate that INZ-701 significantly raised PPi levels in patients with end-stage kidney disease and was well-tolerated.
• Sagar Nigwekar, MD, MMSc, Co-Director, Kidney Research Center, Massachusetts General Hospital, added that the interim results from the SEAPORT 1 trial are encouraging, showing that INZ-701 elevated PPi levels in patients with end-stage kidney disease.

Industry Context

This announcement is significant as it addresses a critical unmet need in the treatment of calciphylaxis, a rare and life-threatening complication of end-stage kidney disease. The positive results for INZ-701 could position Inozyme Pharma as a leader in this therapeutic area, where no approved therapies currently exist. The focus on the PPi-Adenosine pathway is also a novel approach to treating this condition.

Comparison to Industry Standards

• The increase in PPi levels to within the normal range by week 3 is a significant achievement, as many current treatments for ESKD do not directly address this deficiency.
• The reduction in biomarkers of mineral metabolism, such as serum phosphate and FGF-23, is comparable to results seen with other therapies aimed at reducing vascular calcification, but INZ-701's approach is more targeted.
• The safety profile of INZ-701 appears favorable compared to some other treatments for ESKD, which can have significant side effects.
• The planned registrational trial in calciphylaxis is a key step, as there are currently no approved therapies for this condition, making INZ-701 a potential first-in-class treatment.

Stakeholder Impact

• Shareholders will likely view the positive clinical trial results favorably.
• Patients with ESKD and calciphylaxis may benefit from the potential development of INZ-701.
• Employees of Inozyme Pharma may be encouraged by the progress of the company's lead candidate.
• The company's suppliers and partners may see increased business opportunities.

Next Steps

• The company plans to present additional follow-up data at a future medical conference.
• The company plans to initiate a registrational trial of INZ-701 in patients with calciphylaxis in 2025, subject to regulatory alignment and sufficient funding.
• The company expects to complete enrollment of the ENERGY 3 pivotal trial of INZ-701 in pediatric patients with ENPP1 Deficiency by the end of 2024.
• The company anticipates topline data from the ENERGY 3 pivotal trial in early 2026.

Key Dates

Keywords

INZ-701, calciphylaxis, end-stage kidney disease, ESKD, pyrophosphate, PPi, hemodialysis, ENPP1 Deficiency, clinical trial, enzyme replacement therapy, vascular calcification, mineral metabolism